MedTrace Logo

Prisons Evaluation of a One-stop-shop InterVentiOn

NCT04809246 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 541

Last updated 2022-01-14

No results posted yet for this study

Summary

A prospective historically controlled study to assess the effect of an intervention integrating point-of-care hepatitis C (HCV) RNA testing, non-invasive liver fibrosis assessment, fast-tracked direct-acting antiviral (DAA) prescription, and linkage to hepatitis care (a 'one-stop-shop' intervention), on the proportion of participants initiating DAA therapy among people who are recently incarcerated within reception correctional centre(s) in Australia.

Conditions

  • Hepatitis C

Interventions

OTHER

'One-stop-shop' hepatitis clinic

Establishment of a 'one-stop-shop' hepatitis clinic, integrating point-of-care HCV RNA testing, followed by clinical assessment, non-invasive liver fibrosis assessment by fibro-elastography (Fibroscan), and early DAA prescription (for those with chronic HCV) followed by linkage to ongoing hepatitis care, all in the same 60-minute visit.

Sponsors & Collaborators

  • Justice Health & Forensic Mental Health Network NSW Australia

    collaborator UNKNOWN

  • Kirby Institute

    lead OTHER_GOV

Principal Investigators

  • Andrew Lloyd, Prof · Kirby Institute, University NSW

Study Design

Allocation
NON_RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-10-31
Primary Completion
2021-04-23
Completion
2021-09-10

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04809246 on ClinicalTrials.gov